Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDB 1

Drug Profile

BDB 1

Alternative Names: BDB-001 - Beijing Defengrei Biotechnology; BDB-001 injection; BDB-1

Latest Information Update: 07 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Defengrei Biotechnology
  • Developer Beijing Defengrei Biotechnology; Staidson Beijing BioPharmaceuticals
  • Class Anti-inflammatories; Antivirals; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Hidradenitis suppurativa
  • Phase I/II Anti-neutrophil cytoplasmic antibody-associated vasculitis

Most Recent Events

  • 22 Aug 2023 Staidson Beijing Biopharmaceuticals completes the phase II clinical trial in Hidradenitis suppurativa in China (IV) (NCT05093855)
  • 06 Jun 2023 Beijing Defengrei Biotechnology completes a phase I/II trial in Hidradenitis suppurativa in China (NCT05103423)
  • 21 Dec 2022 InflaRx amends co-development agreement with Staidson (Beijing) BioPharmaceuticals for the regulatory approval efforts for BDB 1 in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top